Gabapentin (brand name Neurontin) is one of the most widely prescribed medications in America, dispensed more than 67 million times annually — yet the majority of those prescriptions are for uses the FDA never approved. Originally indicated for epilepsy and postherpetic neuralgia, gabapentin has been massively promoted for chronic pain, anxiety, insomnia, and dozens of other off-label conditions. A July 2025 population-level study now links chronic gabapentin use to significant increases in dementia and mild cognitive impairment, with younger patients facing the steepest risk elevations. Pfizer's subsidiary Warner-Lambert already paid $430 million in 2004 for systematically promoting gabapentin for off-label uses. Litigation is now emerging on behalf of patients who developed cognitive decline after long-term gabapentin use without adequate warnings about neurodegenerative risk.
Litigation Timeline
FDA Class II Gabapentin Recall and Emerging Litigation Wave
In late 2025, the FDA issued a Class II recall for certain lots of gabapentin 100mg capsules due to dissolution failure — a manufacturing defect meaning pills were not releasing the active ingredient properly. While the recall addressed a quality control issue rather than cognitive risk directly, it intensified public and regulatory scrutiny of gabapentin manufacturing and oversight. Simultaneously, pharmaceutical injury attorneys across the country began investigating and filing claims on behalf of patients who developed cognitive decline after chronic gabapentin use, marking the beginning of what may become a major mass tort litigation.
litigationLandmark Study: 29% Increased Dementia Risk, 85% Increased MCI Risk with Chronic Gabapentin Use
A large-scale population-based cohort study published in Regional Anesthesia & Pain Medicine found that patients who filled six or more gabapentin prescriptions had a 29% increased risk of developing dementia and an 85% increased risk of mild cognitive impairment compared to matched controls. The study's most alarming finding involved younger patients: adults aged 35 to 49 experienced a doubling of dementia risk and a tripling of MCI risk. The dose-response relationship and age-stratified findings provided the strongest evidence to date that gabapentin has neurodegenerative potential at commonly prescribed doses. This study became the scientific cornerstone of emerging gabapentin dementia litigation.
scientificFDA Issues Gabapentin Breathing Difficulty Warning — First Major Safety Signal in 26 Years
The FDA issued a Drug Safety Communication warning that gabapentin and pregabalin (gabapentinoids) can cause serious breathing difficulties when combined with opioids or used in patients with respiratory risk factors such as COPD or elderly age. This was the FDA's first significant post-marketing safety action for gabapentin since its 1993 approval, and it acknowledged for the first time that gabapentin's central nervous system depressant effects were clinically more significant than the original labeling suggested. The warning foreshadowed the broader recognition that gabapentin's neurological effects extend beyond its intended mechanism.
regulatory$325 Million Antitrust Settlement — Pfizer's Second Major Gabapentin Penalty
Pfizer agreed to pay $325 million to settle claims by third-party payors (insurance companies, pharmacy benefit managers, and health plans) alleging that the company's anti-competitive conduct delayed generic gabapentin entry and artificially inflated prices. The antitrust settlement, combined with the 2004 DOJ criminal settlement, brought Pfizer's total gabapentin-related legal penalties to over $750 million — yet the company still never conducted a long-term study of the drug's effects on cognitive function. The settlement demonstrated that gabapentin continued to generate massive litigation exposure for Pfizer a full decade after the criminal guilty plea.
litigationPfizer/Warner-Lambert Pays $430 Million for Illegal Off-Label Neurontin Promotion
Pfizer's subsidiary Warner-Lambert pleaded guilty to criminal charges and agreed to pay $430 million to settle allegations that it had illegally promoted Neurontin (gabapentin) for off-label uses including pain, migraines, bipolar disorder, and other conditions for which the drug had not been proven safe or effective. The Department of Justice revealed a systematic marketing campaign involving paid physician speakers, ghost-written journal articles, suppressed negative clinical trials, and lavish incentives for off-label prescribing. Despite this historic penalty, the off-label prescribing patterns Warner-Lambert created became permanently embedded in American medical practice.
litigationFDA Approves Gabapentin for Epilepsy — The Drug That Would Become America's Off-Label Workhorse
The FDA approved gabapentin (brand name Neurontin) as an adjunctive therapy for partial seizures in adults. Developed by Parke-Davis, a division of Warner-Lambert, gabapentin was positioned as a novel anticonvulsant that mimicked the neurotransmitter GABA. The approved indication was narrow — gabapentin was only proven effective as an add-on treatment for patients whose seizures were not controlled by other medications. Within years, however, the drug's manufacturer would systematically promote it for dozens of unapproved conditions, transforming a niche epilepsy drug into one of the most prescribed medications in American history.
regulatoryGet free updates on the Gabapentin Dementia Lawsuit as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Gabapentin Dementia Lawsuit Case Page